금연 치료의 재정영향 분석
The Budgetary Impact of Smoking Cessation Treatment in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Objectives: To estimate the budgetary impact of smoking cessation treatment in Korea in the first 5 years after policy change related to reimbursement of smoking cessation treatment from the healthcare perspective. Methods: In the economic impact model, target populations were adult smokers who were over 20-year old, decided to quit smoking, and took medication for smoking cessation through hospital or clinic visits. Assumed baseline rate of smoking, decision to quit, hospital/clinic visit, and prescription of smoking cessation treatment was 42.1% (male) and 6.2% (female), 55.3%, 5.4%, and 13% respectively. Annual increase rates of smoking, trial to quit smoking, hospital/clinic visits, and prescription of smoking cessation treatment were estimated as -1.8%, 5%, 5%, and 20% respectively during 5 years. Smoking cessation treatments based on three alternatives were estimated: nicotine replacement therapy, bupropion, and varenicline. All drug costs are calculated based on 12-week treatment. Sensitivity analysis was performed to evaluate the impact of varying the smoking rate. Results: Model estimates suggest that the budgetary impact of smoking cessation treatments would be 40 billion KRW in 2014. and in the fifth year after policy change, total smoking cessation programs would be 109 billion KRW in 2019. Conclusion: Reimbursement of smoking cessation treatment could result in additional national budget of 70 billion KRW annually. But we can expect a reduction in the number of smokers would offset this cost by decreasing the burden of smoking.
Abstract
Objectives: To estimate the budgetary impact of smoking cessation treatment in Korea in the first 5 years after policy change related to reimbursement of smoking cessation treatment from the healthcare perspective. Methods: In the economic impact model, target populations were adult smokers who were over 20-year old, decided to quit smoking, and took medication for smoking cessation through hospital or clinic visits. Assumed baseline rate of smoking, decision to quit, hospital/clinic visit, and prescription of smoking cessation treatment was 42.1% (male) and 6.2% (female), 55.3%, 5.4%, and 13% respectively. Annual increase rates of smoking, trial to quit smoking, hospital/clinic visits, and prescription of smoking cessation treatment were estimated as -1.8%, 5%, 5%, and 20% respectively during 5 years. Smoking cessation treatments based on three alternatives were estimated: nicotine replacement therapy, bupropion, and varenicline. All drug costs are calculated based on 12-week treatment. Sensitivity analysis was performed to evaluate the impact of varying the smoking rate. Results: Model estimates suggest that the budgetary impact of smoking cessation treatments would be 40 billion KRW in 2014. and in the fifth year after policy change, total smoking cessation programs would be 109 billion KRW in 2019. Conclusion: Reimbursement of smoking cessation treatment could result in additional national budget of 70 billion KRW annually. But we can expect a reduction in the number of smokers would offset this cost by decreasing the burden of smoking.
참고문헌 (21)
- 정금지, "한국인 성인 남녀의 흡연관련 사망에 관한 연구", 보건정보통계학회지, 38(2), pp.36~48 (2013), 한국보건정보통계학회
- "국민건강영양조사 2013년도 결과 발표"[URL]
- 담배 제조 및 매매 금지: 문제점과 대책, "박재갑", 국립암센터, ~ (2006)
- 김수정, "흡연의 사회적 비용 분석: 2006년을 기준으로", 정책분석평가학회보, 18(4), pp.119~140 (2008), 한국정책분석평가학회
- 이진석, "최근의 금연정책으로 인한 흡연 관련 질병 발생 감소와 비용 절감", 박사, 의료관리학, pp.2006
- Bae JY, "Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea", Value Health, 12(Suppl 3), pp.S70~S73 (2009)
- von Wartburg M, "The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada", Int J Clin Pract, 68, pp.639~646 (2014)
- Athanasakis K, "Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece", Clin Ther, 34, pp.1803~1814 (2012)
- Knight C, "The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective", Acta Clin Belg, 67, pp.416~422 (2012)
- Hettle R, "Cost-effectiveness of varenicline compared to placebo as an aid to smoking cessation in patients with cardiovascular disease", Open Pharmacoeconomics and Health Economics Journal, 4, pp.8~17 (2012)
- Linden K, "Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers", Curr Med Res Opin, 26, pp.549~560 (2010)
- Annemans L, "Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis", Clin Drug Investig, 29, pp.655~665 (2009)
- Hoogendoorn M, "Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands", Curr Med Res Opin, 24, pp.51~61 (2008)
- Králíková E, "Smoking cessation: a European perspective", Vascular Health and Risk Management, 4(Suppl 1), pp.1~23 (2008)
- Paradis PE, "Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment", Healthc Q, 15, pp.52~60 (2012)
- "관계부처 합동 보도자료. 범(凡)정부, 「금연 종합대책」 발표"[URL]
- "가정별, 연령별(전국)추계인구"[URL]
- 보건복지부, "2012 국민건강통계", ~ (2013)
- 보건복지부, "2012년도 국가 흡연 예방 및 금연 사업 안내", ~
- 2009년 하반기 흡연 실태 조사, "보건복지부", ~
- "금연 치료제 경험 흡연자 10명중 2명 뿐"[URL]